ARCHIVES

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

This article is from The Cancer Letter archive.

Vol. 27 No. 09 | March 2, 2001

Download PDF Visit The Full Archive

Related Articles

House, Senate Must Resolve Major Differences In Authorization Bills

September 12, 1980

Three Organizations Publish Guideline For Biomarker Testing for Targeted Therapies

April 26, 2013

Accelerated Approval In Oncology Shaves A Year Off Development Time, FDA Data Show

October 30, 2009

The March, Sept. 26: Events Planned In D.C., Around The U.S.

September 4, 1998

Fox Chase, UCLA, U. Washington Win Neutron Contracts

October 5, 1979

HHS Inquiry Triggers Sloppy Stories On Gallo’s Laboratory

July 21, 1989